&nbsp;

Drugs Used:

Quick Link(s):

Regimen Monograph

Nov 2024

Regimen

BEP(5D)

Cancer Type:

Gynecologic,

Germ Cell

Intent: Adjuvant

Drugs Used:

Quick Link(s):

Regimen Monograph

Dec 2021

Regimen

BLIN

Cancer Type:

Hematologic,

Leukemia - Acute Lymphoblastic (ALL)

Intent: Palliative

Funding:

New Drug Funding Program

Blinatumomab - Relapsed or Refractory Acute Lymphoblastic Leukemia (Ph+ BCP-ALL)

New Drug Funding Program

Blinatumomab - Relapsed or Refractory Acute Lymphoblastic Leukemia (Ph- BCP-ALL)

Drugs Used:

blinatumomab

Quick Link(s):

Regimen Monograph

Oct 2024

Regimen

BAC+RITU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma

Drugs Used:

riTUXimab,

bendamustine (PDRP prior authorization),

cytarabine,

riTUXimab (subcut)

Quick Link(s):

Regimen Monograph

Aug 2020

Regimen

BEVA

Cancer Type:

Gynecologic,

Ovary

Intent: Palliative

Funding:

New Drug Funding Program

Bevacizumab (Biosimilar) with Paclitaxel and Carboplatin - Front-line Treatment (Previously Untreated) Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Drugs Used:

bevacizumab

Quick Link(s):

Regimen Monograph

Jul 2024

Regimen

BORT(MNT)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Drugs Used:

bortezomib (Compassionate)

Quick Link(s):

Regimen Monograph

Nov 2024

Regimen

LENV

Cancer Type:

Endocrine,

Thyroid

Intent: Palliative

Funding:

Exceptional Access Program

lenvatinib - For the treatment of patients with locally recurrent or metastatic, progressive, radioactive-iodine-refractory differentiated thyroid cancer (DTC) according to criteria

Drugs Used:

lenvatinib

Quick Link(s):

Regimen Monograph

Sep 2020

Regimen

BEP(5D)PACL

Cancer Type:

Gynecologic,

Germ Cell

Intent: Curative

Drugs Used:

Quick Link(s):

Regimen Monograph

May 2019

Regimen

BREN(CONS)

Cancer Type:

Hematologic,

Lymphoma - Hodgkin

Intent: Curative

Funding:

New Drug Funding Program

Brentuximab Vedotin - Consolidation Post-Autologous Stem Cell Transplant (ASCT) for Hodgkin Lymphoma

Drugs Used:

brentuximab vedotin

Quick Link(s):

Regimen Monograph

Sep 2024

Regimen

LANR

Cancer Type:

Gastrointestinal,

Neuroendocrine (GI),

Lung,

Neuroendocrine (Lung)

Intent: Palliative

Funding:

ODB - General Benefit

lanreotide

Drugs Used:

lanreotide

Quick Link(s):

Regimen Monograph

May 2024

Regimen

LETRPALB

Cancer Type:

Breast

Intent: Palliative

Funding:

Exceptional Access Program

palbociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant, according to clinical criteria

ODB - General Benefit

letrozole

Drugs Used:

palbociclib,

letrozole